Return to Main Menu

Rheumatoid arthritis study targets African Americans  MUSC is one of four major academic medical centers in the southeast United States which will soon be gathering data for investigators interested in the genetics of rheumatoid arthritis (RA) in African Americans, with support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).  The institute, a component of the National Institutes of Health (NIH), has awarded a research contract for the Consortium for the Longitudinal Evaluations of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry to the University of Alabama at Birmingham (UAB).  Other participating centers are Emory University and the University of North Carolina. MUSC investigators are Edwin Smith, M.D., and Gary Gilkeson, M.D.  The registry will provide clinical and X-ray data and DNA to help scientists analyze genetic and nongenetic factors that might predict disease course and outcomes of RA in this population.  Certain genes that play a role in the immune system are associated with a tendency to develop RA. Some individuals without these genes may develop this disease, while others who possess the genes never develop RA. Scientists believe that some environmental factors may play a part, triggering the disease process in people whose genetic makeup makes them susceptible to RA. The investigators intend to register 600 participants. Since there are currently no ongoing studies evaluating early RA in African Americans, the investigators have focused on this population.  African Americans are under-represented in most clinical studies, including current observational studies of people with RA.  “Identifying any factor, genetic or otherwise, that may predispose an individual to rheumatoid arthritis or provide clues to an individual's disease outcome will greatly improve our efforts to treat and ultimately prevent this disease which affects so many people,” said Stephen I Katz, M.D., Ph.D., NIAMS director. “This registry of African Americans with early RA will be critical in identifying risk factors, including genetic and environmental, that point to a more aggressive disease,” said Larry Moreland, M.D., principal investigator of the CLEAR Registry. “Ultimately, the ability to identify patients very early in the disease process who might have a worse long-term outcome will allow physicians to provide better treatments for these patients.” RA is an autoimmune disease in which the body's immune system attacks its own tissues. It occurs in all races and ethnic groups, and affects about two to three times as many women as men. Scientists estimate that RA affects the lives of one percent of the adult population in the United States, although young adults and children can also be affected.  Symptoms and severity vary greatly among individuals, and may include inflammation, pain, swelling, stiffness and progressive loss of function in the joints. It may also cause fatigue, occasional fever and a general sense of not feeling well. In some cases, the internal organs and systems can become involved and ultimately damaged. Patient enrollment for the registry is projected to begin in late spring 2001.